Inventor · disambiguated record
Giordano Caponigro
Also filed as: CAPONIGRO GIORDANO · CAPONIGRO GIORDANO M · CAPONIGRO GIORDANO MICHAEL
15 granted patents·24 pending applications·68 citations·filing 1997–2023
91Inventor score
Files withNOVARTIS AG25CAPONIGRO GIORDANO6ARRAY BIOPHARMA INC5DELTAGEN PROTEOMICS1DELTAGEN PROTEOMICS INC1
Top patents by PatentIndex Score
39 records- 0189US10973829B2Therapeutic uses of a C-RAF inhibitorNOVARTIS AG·Filed 2017·Granted Apr 13, 2021·4 cites·12 claims
- 0289US10485788B2Pharmaceutical combinationsARRAY BIOPHARMA INC·Filed 2018·Granted Nov 26, 2019·5 cites·23 claims
- 0386US10328066B2Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancerNOVARTIS AG·Filed 2016·Granted Jun 25, 2019·5 cites·2 claims
- 0485US12011449B2Therapeutic combinations comprising a c-RAF inhibitorNOVARTIS AG·Filed 2021·Granted Jun 18, 2024·1 cites·8 claims
- 0584US10548894B2Combination therapyARRAY BIOPHARMA INC·Filed 2018·Granted Feb 4, 2020·5 cites·26 claims
- 0684US9700557B2Pharmaceutical combinations of a CDK4/6 inhibitor and a B-RAF inhibitorNOVARTIS AG·Filed 2013·Granted Jul 11, 2017·13 cites·13 claims
- 0783US9913844B2Combination therapyNOVARTIS AG·Filed 2014·Granted Mar 13, 2018·7 cites·3 claims
- 0883US9867825B2Pharmaceutical combination comprising binimetinibNOVARTIS AG·Filed 2013·Granted Jan 16, 2018·5 cites·12 claims
- 0983US9474754B2Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitorCAPONIGRO GIORDANO·Filed 2013·Granted Oct 25, 2016·7 cites·16 claims
- 1080US6582899B1Methods for identifying agents that cause a lethal phenotype, and agents thereofDELTAGEN PROTEOMICS INC·Filed 2000·Granted Jun 24, 2003·9 cites·30 claims
- 1171US11376239B2Pharmaceutical combinationsARRAY BIOPHARMA INC·Filed 2019·Granted Jul 5, 2022·0 cites·16 claims
- 1271US2022280523A1Combination of pi3k inhibitor and c-met inhibitorNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1370US2023398115A1Mdm2 inhibitors and combinations thereofNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1470US2023044943A1Pharmaceutical CombinationsARRAY BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 1568US2020246338A1Combination therapyARRAY BIOPHARMA INC·Filed 2019·Application pending·0 cites
- 1663US2020253980A1Combination of pi3k inhibitor and c-met inhibitorNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1761US2021260059A1Mdm2 inhibitors and combinations thereofNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1861US2019350935A1Combination of PI3K inhibitor and c-MET inhibitorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1959US2019083500A1Combination of PI3K Inhibitor and C-Met InhibitorNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2057US2021186973A1Combination of ribociclib and dabrafenib for treating or preventing cancerNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2156US2023321110A1Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcomaNOVARTIS AG·Filed 2021·Application pending·0 cites
- 2254US2023226030A1Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclcNOVARTIS AG·Filed 2021·Application pending·0 cites
- 2354US2019060309A1Mdm2 inhibitors and combinations thereofNOVARTIS AG·Filed 2016·Application pending·0 cites
- 2454US2024000789A1Therapeutic combinations comprising a craf inhibitorNOVARTIS AG·Filed 2021·Application pending·0 cites
- 2551US2015216870A1Combination of PI3K Inhibitor and C-Met InhibitorCAPONIGRO GIORDANO·Filed 2013·Application pending·0 cites
- 2647US11406627B2Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancersNOVARTIS AG·Filed 2018·Granted Aug 9, 2022·0 cites·17 claims
- 2747US10011874B2Androgen receptor mutationNOVARTIS AG·Filed 2014·Granted Jul 3, 2018·0 cites·2 claims
- 2844US2018250302A1Combination of ribociclib and dabrafenib for treating or preventing cancerCAPONIGRO GIORDANO·Filed 2016·Application pending·0 cites
- 2944US2019175609A1Therapeutic uses of a c-raf inhibitorNOVARTIS AG·Filed 2017·Application pending·0 cites
- 3044US2018066322A1Biomarkers associated with cdk inhibitorsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 3141US2015322528A1Biomarkers associated with cdk inhibitorsCAPONIGRO GIORDANO·Filed 2013·Application pending·0 cites
- 3239US2018318275A1Combination therapy using pi3k inhibitor and mdm2 inhibitorNOVARTIS AG·Filed 2016·Application pending·0 cites
- 3338US6623922B1Methods for identifying, characterizing, and evolving cell-type specific CIS regulatory elementsDELTAGEN PROTEOMICS·Filed 1997·Granted Sep 23, 2003·7 cites·12 claims
- 3437US2002045188A1Methods for validating polypeptide targets that correlate to cellular phenotypesFiled 2001·Application pending·0 cites
- 3536US10328065B2Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancerNOVARTIS AG·Filed 2016·Granted Jun 25, 2019·0 cites·3 claims
- 3634US2018243304A1Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancerNOVARTIS AG·Filed 2016·Application pending·0 cites
- 3734US2012258940A1Method for treating haematological cancersCAPONIGRO GIORDANO·Filed 2010·Application pending·0 cites
- 3834US2019365741A1Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancerNOVARTIS AG·Filed 2016·Application pending·0 cites
- 3930US2018256557A1Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancerCAPONIGRO GIORDANO·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Giordano Caponigro files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →